James Isaacs, MD
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma (NCT06190249) | James Isaacs, MD | 2024-12-02 |
Track James Isaacs, MD automatically
Every clearance here is in the API, with alerts when new ones post.